A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCEND
  • Sponsors InterMune
  • Most Recent Events

    • 12 Sep 2017 Results of a pooled CAPACITY and ASCEND trials were presented at the European Respiratory Society (ERS) congress, according to Roche media release.
    • 12 Sep 2017 Resultsof a pooled CAPACITY and ASCEND trials published in the Roche Media Release
    • 24 May 2017 Results (n=1247) of pooled analysis comparing the effect of pirfenidone on progression-free survival (PFS) using a pre-specified PFS definition versus a novel definition of PFS using data from phase III trials (ASCEND or CAPACITY), presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top